Summary of Talk:
To discuss the concept of big data analysis and its application in the medical field. How we apply big data analysis to guild policy formulation, clinical practice and precision medicines
Dr. Jianwei Xuan has more than 20 years of research, teaching, and global leadership experience in major Universities such as Sun Yat-sen University, University of Florida, Fudan University, and several multinational pharmaceutical companies such as Pfizer, GSK, etc. Jianwei has led multiple global health economic and market access teams and conducted high impact health policy, health economics, comparative effectiveness, outcomes research, epidemiology and market access researches to support evidence-based decision-making process. Research results have been adapted in numerous countries to support formulating national health care policy, designing drug reimbursement formulary and supporting government decision making. Before entering industry, he worked as medical reviewers in China FDA for more than 6 years. Dr. Xuan is also very familiar with drug development process, global regulatory affair, and safety requirements.
With more than 20 years of working/research experience, Dr. Xuan also published extensively in health economic, market access, outcomes research, epidemiology, pharmacovigilance, and mobile health areas. He has established extensive professional network with global key opinion leaders and led numerous global policy forums, advisory boards, and government/payer panel discussions. He is current Chair of ISPOR Asia consortium advisory committee. He also has extensive teaching and graduate student advising experience in advising Ph.D. students and training government officials, researchers, and various health care service researchers.
Dr. Xuan obtained his Ph.D. in Health Economics from School of Public Health, University of North Carolina at Chapel Hill and completed his medical degree in Shanghai Medical University, China.